艾锐威特生物制药

最新新闻

• 评级变动
  Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Alterity Therapeutics (ATHE)
  TipRanks · 2026/8/13
• 评级变动
  Analysts Conflicted on These Healthcare Names: ArriVent BioPharma, Inc. (AVBP), Zimmer Biomet Holdings (ZBH) and Tecan Group AG (OtherTCHBF)
  TipRanks · 2026/8/14
• 评级变动
  Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Protagonist Therapeutics (PTGX) and Resmed (RMD)
  TipRanks · 2026/6/22
• 评级变动
  H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $47
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS) and ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/9/15
• 评级变动
  BTIG Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/7/15
• 评级变动
  A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/14
• 评级变动
  Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  JonesTrading Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• ArriVent BioPharma, Inc. (AVBP) Gets a Buy From Guggenheim
  TipRanks · 2026/9/15
• Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/9/15
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Kyverna Therapeutics, Inc. (KYTX) and ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/8/14
• 评级变动
  Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Cuts Target Price to $40
  \u5e02\u573a\u8d44\u8baf · 2026/8/15
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Danaher (DHR), ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/7/22
• Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Analysts Offer Insights on Healthcare Companies: AgomAb Therapeutics NV ADR (AGMB), Nuvation Bio (NUVB) and ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/9/15
• A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $40 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP)
  TipRanks · 2026/7/14
• 评级变动
  A Quick Look at Today's Ratings for ArriVent BioPharma(AVBP.US), With a Forecast Between $42 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。